Achieve Life Sciences Inc (ACHV NASDAQ) stock market data APIs
$4.5608
0.07(1.5%)
as of November 7, 2025
Try our APIs with
free plan!
Achieve Life Sciences Inc Financial Data Overview
Price chart is built with
Anychart
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Prev. Close
4.5608
Open
4.6327
High
4.6327
Low
4.2817
52 wk Range
1.84-5.78
Market Cap
235 M
Shares Outstanding
51 105 K
EPS
-0.28
Beta
1.692
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Achieve Life Sciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Achieve Life Sciences Inc data using free add-ons & libraries
Get Achieve Life Sciences Inc Fundamental Data
Achieve Life Sciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -52 116 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.244
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Achieve Life Sciences Inc News
New
Achieve Life Sciences outlines expedited FDA review for cytisinicline and targets Q3/Q4 2026 launch
Earnings Call Insights: Achieve Life Sciences (ACHV) Q3 2025 MANAGEMENT VIEW * CEO Richard A. Stewart described the quarter as "another truly significant quarter for Achieve in our mission to get ...
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2...
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation
120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully Concluded DSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, Briti...
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025
SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
